A total of 1,747 requests for the prescription of the drug Mounjaro, involving 972 patients, were submitted to the Health Insurance Organization (OAY) from January 1, 2025, through August 20, 2026, with 238 of the 422 applications that had been evaluated being approved, according to a written statement by Sophia Petridou, Senior Officer of the Agency’s Medicines Directorate.
Ms. Petridou states that as of October 15, 2026, the pharmaceutical product Mounjaro (tirzepatide) will be included in the General Health System (GeSY) List of Pharmaceutical Products and will be reimbursed, based on approved protocols, both for the treatment of type II diabetes and for the management of obesity in adults.
ΣΧΕΤΙΚΑ ΑΡΘΡΑ
As noted, the drug’s inclusion marks a shift from the previous process of reviewing individual requests to a defined reimbursement framework, with specific criteria and pre-approval procedures.
“The new reimbursement option for obesity applies to specific cases that meet the criteria of the relevant protocol and does not generally apply to the use of the drug for weight loss,” clarifies Ms. Petridou.
READ ALSO: Mounjaro through the National Health System (GESY): What’s changing starting today, who is eligible for treatment, and for how long
Prescriptions will be issued by specific medical specialties, following approval of a pre-authorization request by the OAY, while the medication will be available, until further notice, through hospital pharmacies.
At the same time, as noted, “the inclusion of Mounjaro also reflects the increased need observed recently,” noting that from January 1, 2025, through August 20, 2026, a total of 1,747 requests for Mounjaro were submitted, involving 972 patients, while 422 requests had been evaluated, resulting in 238 approvals and 184 rejections.
“The decision to include the drug in the National Health Insurance Fund is part of the OAU’s ongoing effort to adapt its services and treatment options to the changing needs of beneficiaries, based on scientific data and clear criteria, while ensuring the rational and responsible use of the National Health System’s resources,” it concludes.
